SVNS — Solvonis Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Solvonis Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 7 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.954 | -2.71 | -3.12 | -1.59 | -5.74 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.008 | 0.872 | 1.29 | 0.487 | 3.06 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.646 | -0.64 | 0.413 | -0.027 | -0.589 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0.254 | -2.36 | -1.24 | -1.13 | -3.27 |
| Capital Expenditures | -0.001 | -0.718 | -0.232 | -0.324 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | -0.013 | 0 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Cash from Investing Activities | -0.001 | -0.718 | -0.232 | -0.337 | 0 |
| Financing Cash Flow Items | — | -0.34 | 0 | -0.041 | -0.039 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.8 | 4.13 | 0 | 2.08 | 4.23 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.559 | 1.04 | -1.49 | 0.602 | 0.963 |